JAK/STAT Signaling in Hepatocellular Carcinoma

Overview

Journal Hepat Oncol

Date 2020 Apr 11

PMID 32273976

Citations 68

Authors

Justin Jit Hin Tang

Dexter Kai Hao Thng

Jhin Jieh Lim

Tan Boon Toh

Affiliations

Soon will be listed here.

Abstract

Liver cancer is the second most lethal cancer in the world with limited treatment options. Hepatocellular carcinoma (HCC), which accounts for more than 80% of all liver cancers, has had increasing global incidence over the past few years. There is an urgent need for novel and better therapeutic intervention for HCC patients. The JAK/STAT signaling pathway plays a multitude of important biological functions in both normal and malignant cells. In a subset of HCC, JAK/STAT signaling is aberrantly activated, leading to dysregulation of downstream target genes that controls survival, angiogenesis, stemness, immune surveillance, invasion and metastasis. In this review, we will focus on the role of JAK/STAT signaling in HCC and discuss the current clinical status of several JAK/STAT inhibitors.

Citing Articles

Dose-Dependent PFESA-BP2 Exposure Increases Risk of Liver Toxicity and Hepatocellular Carcinoma.

Kostecki G, Chuang K, Buxton A, Dakshanamurthy S Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996819 PMC: 11854358. DOI: 10.3390/cimb47020098.

Hepatocellular carcinoma: signaling pathways and therapeutic advances.

Zheng J, Wang S, Xia L, Sun Z, Chan K, Bernards R Signal Transduct Target Ther. 2025; 10(1):35.

PMID: 39915447 PMC: 11802921. DOI: 10.1038/s41392-024-02075-w.

The novel role of LOC344887 in the enhancement of hepatocellular carcinoma progression via modulation of SHP1-regulated STAT3/HMGA2 signaling axis.

Lin Y, Chi H, Wu M, Liao C, Chen C, Huang P Int J Biol Sci. 2024; 20(15):6281-6296.

PMID: 39664573 PMC: 11628343. DOI: 10.7150/ijbs.99683.

Bioinformatics combined with network pharmacology and experimental validation to identify key biomarkers of hepatocellular carcinoma and corresponding compounds in Radix Astragali and Pueraria Mirifica.

Li M, Liu B, Xian M, Wang S, Liu P Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39549064 DOI: 10.1007/s00210-024-03597-4.

Therapeutic potential of targeting protein tyrosine phosphatases in liver diseases.

Wang A, Zhang Y, Lv X, Liang G Acta Pharm Sin B. 2024; 14(8):3295-3311.

PMID: 39220870 PMC: 11365412. DOI: 10.1016/j.apsb.2024.05.006.

References

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

McGlynn K, Petrick J, London W . Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19(2):223-38. PMC: 4712629. DOI: 10.1016/j.cld.2015.01.001. View

Ji Y, Liu Y, Xue N, Du T, Wang L, Huang R . Cryptotanshinone inhibits esophageal squamous-cell carcinoma in vitro and in vivo through the suppression of STAT3 activation. Onco Targets Ther. 2019; 12:883-896. PMC: 6357882. DOI: 10.2147/OTT.S187777. View

Murray P . The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007; 178(5):2623-9. DOI: 10.4049/jimmunol.178.5.2623. View

Han Z, Liu S, Lin H, Trivett A, Hannifin S, Yang D . Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses. Cancer Immunol Immunother. 2019; 68(7):1073-1085. PMC: 6584221. DOI: 10.1007/s00262-019-02338-4. View

Huynh J, Chand A, Gough D, Ernst M . Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat Rev Cancer. 2018; 19(2):82-96. DOI: 10.1038/s41568-018-0090-8. View

Llovet J, Montal R, Sia D, Finn R . Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15(10):599-616. DOI: 10.1038/s41571-018-0073-4. View

Reilley M, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y . STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018; 6(1):119. PMC: 6240242. DOI: 10.1186/s40425-018-0436-5. View

10.

Yoo C, Kang J, Lim H, Kim J, Lee M, Lee K . Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Res Treat. 2018; 51(2):510-518. PMC: 6473286. DOI: 10.4143/crt.2018.226. View

11.

Carbajo-Pescador S, Ordonez R, Benet M, Jover R, Garcia-Palomo A, Mauriz J . Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer. 2013; 109(1):83-91. PMC: 3708553. DOI: 10.1038/bjc.2013.285. View

12.

Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C . Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012; 119(20):4614-8. PMC: 4081383. DOI: 10.1182/blood-2011-12-400051. View

13.

Zhang C, Guo F, Xu G, Jia W, Ge Y . STAT3 activation mediates epithelial-to-mesenchymal transition in human hepatocellular carcinoma cells. Hepatogastroenterology. 2015; 61(132):1082-9. View

14.

Kotha A, Sekharam M, Cilenti L, Siddiquee K, Khaled A, Zervos A . Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther. 2006; 5(3):621-9. DOI: 10.1158/1535-7163.MCT-05-0268. View

15.

Calvisi D, Ladu S, Gorden A, Farina M, Conner E, Lee J . Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006; 130(4):1117-28. DOI: 10.1053/j.gastro.2006.01.006. View

16.

Llovet J, Schwartz M, Mazzaferro V . Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005; 25(2):181-200. DOI: 10.1055/s-2005-871198. View

17.

Cheng J, Deng Y, Yi H, Wang G, Fu B, Chen W . Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation. Oncogenesis. 2016; 5:e198. PMC: 5154347. DOI: 10.1038/oncsis.2016.7. View

18.

Lee C, Cheung S . STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma. Cancers (Basel). 2019; 11(11). PMC: 6895841. DOI: 10.3390/cancers11111646. View

19.

Hosui A, Kimura A, Yamaji D, Zhu B, Na R, Hennighausen L . Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-{beta} and STAT3 activation. J Exp Med. 2009; 206(4):819-31. PMC: 2715112. DOI: 10.1084/jem.20080003. View

20.

Wrzesinski S, Taddei T, Strazzabosco M . Systemic therapy in hepatocellular carcinoma. Clin Liver Dis. 2011; 15(2):423-41, vii-x. PMC: 3758582. DOI: 10.1016/j.cld.2011.03.002. View